Judge Invalidates Reissue Patent For Pfizer's Celebrex

Law360, Washington (March 12, 2014, 7:05 PM EDT) -- A Virginia federal judge on Wednesday invalidated a key Pfizer Inc. reissue patent covering methods for administering its blockbuster arthritis drug Celebrex, a ruling exposing the company to competition from generics makers.

U.S. District Judge Arenda L. Wright Allen said that U.S. Patent Number RE44048 was invalid under the judicial doctrine of obviousness-type double patenting, which prohibits a party from obtaining a new patent with claims that are not patentability distinct from claims in an earlier patent, according to an order granting partial summary judgment....
To view the full article, register now.